SRPT new CEO Michael Severino, on his first earnings call, notes September will be the 10-year anniversary of the Exondys approval. One of t
SRPT new CEO Michael Severino, on his first earnings call, notes September will be the 10-year anniversary of the Exondys approval. One of the first questions to him from an analyst: Will you consider separating the DMD business from the sRNA research programs? Adam F X post
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.